We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

argenx SE (ARGX) ADR Each Representing 1 Ord Share SPON

Sell:$382.20 Buy:$382.95 Change: $16.01 (4.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $16.01 (4.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $16.01 (4.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Contact details

Laarderhoogtweg 25
1101 EB
+31 (76) 3030

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$22.08 billion
Shares in issue:
59.39 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Tim Van Hauwermeiren
    Chief Executive Officer, Co-Founder, Executive Director
  • Karl Gubitz
    Chief Financial Officer
  • Karen Massey
    Chief Operating Officer
  • Peter Ulrichts
    Chief Scientific Officer
  • Arjen Lemmen
    Vice President - Corporate Development and Strategy
  • Malini Moorthy
    General Counsel
  • Luc Truyen
    Chief Medical Officer
  • Andria Wilk
    Global Head of Quality

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.